

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

NOTICE OF THE 2023 FIRST EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2023 first extraordinary general meeting (the “EGM”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “Company”) will be held at 2:00 p.m. on Friday, December 15, 2023 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the circular of the Company dated November 24, 2023.

SPECIAL RESOLUTION

1. To consider and approve the amendments to the articles of association and related rules and procedures of the Company;

ORDINARY RESOLUTION

2. To consider and approve the change in use of proceeds from the H share listing of the Company:
 - (a) RMB528.9 million (or approximately 61.36% of the unutilized Net Proceeds) is intended to be used for expansion of the sales and marketing network and infrastructure in the European Union and other global markets, such as the PRC; and for expansion of production scale and organization and increase in procurement and reserves of production resources;
 - (b) RMB203.0 million (or approximately 23.55% of the unutilized Net Proceeds) is intended to be used for expanding our development and manufacturing capacity and broadening our product and services offering of Cytovance;

- (c) RMB80.0 million (or approximately 9.28% of the unutilized Net Proceeds) is intended to be used for investment in innovative drugs; and
- (d) RMB50.0 million (or approximately 5.80% of the unutilized Net Proceeds) is intended to be used as general working capital of the Company to support the expansion of production lines, the improvement of supply chain management and the payment of bank loans, or, subject to permission under the PRC laws and regulations, the balance to be placed with PRC financial institutions as short-term deposits before actual use of the Net Proceeds.

SPECIAL RESOLUTION

- 3. To consider and approve the proposed adjustment to the application for credit line and providing guarantee to certain banks.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
November 24, 2023

Notes:

- 1. For the purpose of holding the EGM, the H Share register of members of the Company will be closed from Tuesday, December 12, 2023 to Friday, December 15, 2023 (both days inclusive), during which period no transfer of H Shares can be registered. In order for H Share Shareholders to be qualified to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the H Share registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, no later than 4:30 p.m. on Monday, December 11 2023 for registration. The Shareholders whose names appear on the register of members of the Company on Friday, December 15, 2023 are entitled to attend and vote at the EGM.
- 2. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalves. A proxy needs not be a Shareholder.
- 3. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his/her attorney duly authorized in writing. If the Shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
- 4. In order to be valid, the proxy form must be deposited, for H Share Shareholders, to the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the time for holding the EGM. If the proxy form is signed by a person under a power of attorney or other authority, a notarized copy of that power of attorney or other authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude the Shareholders from attending and voting in person at the EGM or any adjourned meetings should they so wish.

5. Shareholders shall produce their identification documents and supporting documents in respect of the Shares held when attending the EGM. If corporate Shareholders appoint authorised representative to attend the EGM, the authorized representative shall produce his/her identification documents and a notarized copy of the relevant authorization instrument signed by the board of directors or other authorised parties of the corporate Shareholders or other notarized documents allowed by the Company. Proxies shall produce their identification documents and the proxy form signed by the Shareholders or their attorney when attending the EGM.
6. The EGM is expected to take for less than half a day. Shareholders attending the EGM shall be responsible for their own travel and accommodation expenses.
7. All voting at the EGM will be conducted by poll.

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.